Search
dalfampridine (Ampyra)
Indications:
- improve walking in multiple sclerosis
Contraindications:
- moderate-severe renal insufficiency
Dosage:
- 10 mg PO BID
Pharmacokinetics:
- eliminated by kidney
Adverse effects:
- seizures (dose-related) [2]
- majority of seizures occur within days to weeks
Mechanism of action:
- active ingredient is 4-aminopyridine
- blocks K+ channels in demyelinated neurons, restoring conductivity
General
neurologic agent
4-aminopyridine (fampridine)
References
- FDA NEWS RELEASE, Jan. 22, 2010
FDA Approves Ampyra to Improve Walking in Adults with Multiple
Sclerosis
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198463.htm
- FDA MedWatch, July 23, 2012
Ampyra (dalfampridine): Drug Safety Communication - Seizure
Risk for Multiple Sclerosis Patients
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm313055.htm
- Egeberg MD, Oh CY, Bainbridge JL.
Clinical overview of dalfampridine: an agent with a novel
mechanism of action to help with gait disturbances.
Clin Ther. 2012 Nov;34(11):2185-94
PMID: 23123001
- Goodman AD, Brown TR, Edwards KR et al
A phase 3 trial of extended release oral dalfampridine in
multiple sclerosis.
Ann Neurol. 2010 Oct;68(4):494-502.
PMID: 20976768
- Ampyra, Acorda Therapeutics, Inc, Physician Resources
http://ampyra-hcp.com/hcp/physician_resources/